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The Finnish new variant of  Chlamydia trachoma-
tis (FI-nvCT) is escaping diagnostics in Finland, Norway 
and Sweden. We have developed and validated an 
Aptima-format nucleic acid amplification test (NAAT) 
designed specifically to detect the FI-nvCT. This NAAT 
has high sensitivity (100%) and specificity (100%) for 
the FI-nvCT strain, enabling further investigation of 
the geographic distribution, prevalence and transmis-
sion of this diagnostic-escape mutant in screening 
populations in Europe.
In February 2019, investigation of discrepant nucleic 
acid amplification test (NAAT) results led to the dis-
covery of a new genetic variant strain of  Chlamydia 
trachomatis  in south-western Finland [1]. This strain, 
designated Finnish new variant of  C. trachoma-
tis  (FI-nvCT), harbours a single nt base mutation 
(C1515T; Escherichia coli numbering) in 23S rRNA. This 
mutation was determined to be the root cause for com-
promised detection of the organism by the Aptima 
Combo 2 (AC2) diagnostic test (Hologic Inc., San Diego, 
California, United States (US)), which targets  C. tra-
chomatis 23S rRNA [2,3]. Archived and newly received 
clinical specimens in Finland and Sweden with equivo-
cal results or high-negative relative light units (RLU) 
from 15 to 99 in the AC2 test, and discrepant results 
between AC2 (target: 23S rRNA) and the separate 
Aptima  Chlamydia trachomatis  (ACT) test (target: 16S 
rRNA) (i.e. AC2 negative/equivocal—ACT positive) sig-
nalled the presence of the new strain. Data collected 
in subsequent investigations suggested a recent emer-
gence of FI-nvCT in south-western Finland, Norway 
and Sweden with relatively low prevalence (ca 1–6%) 
among patients with  C. trachomatis  infections [1,3-5]. 
We have developed and validated a research-use only 
Aptima-format surveillance NAAT designed specifically 
to detect the FI-nvCT strain. This assay should facilitate 
further investigations to determine the geographic dis-
tribution, prevalence and transmission of this diagnos-
tic-escape mutant.
 
New Aptima-format surveillance assay 
for the Finnish new variant of Chlamydia 
trachomatis
To understand the geographic distribution, preva-
lence and transmission dynamics of the FI-nvCT strain 
nationally and internationally, we have developed 
an Aptima-format NAAT that sensitively and specifi-
cally detects FI-nvCT (23S rRNA gene C1515T muta-
tion) but not wild-type (C1515)  C. trachomatis  strains. 
This research-use only test uses target capture and 
transcription-mediated amplification chemistries on 
the automated Panther instrument (Hologic Inc.) to 
isolate and amplify  C. trachomatis  23S rRNA, and an 
acridinium ester probe to selectively detect the C→T 
mutation at position 1515.
 
Validation and verification results for the 
Aptima-format surveillance assay for the 
Finnish new variant of C. trachomatis 
All validation and verification studies of the new 
FI-nvCT assay were conducted according to Clinical 
Laboratory Standards Institute (CLSI) standard pro-
tocols used for in vitro diagnostic assay validation 
[6]. The cut-off value of the test (100,000 RLU) was 
initially established by testing 454 de-identified rem-
nant clinical specimens obtained from a large refer-
ence laboratory in the US. The collection consisted of 
266 specimens (endocervical and vaginal swabs, male 
and female urine, PreservCyt ThinPrep liquid cytol-
ogy) positive for C. trachomatis by the AC2 assay, and 
188 specimens (mixed types) that were AC2-negative 
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(Figure 1). Signal-to-cut-off (S/CO) ratio values for all 
clinical specimens tested ranged from 0 to 0.45. Mean 
S/CO ratio values ranged from 0.02 to 0.071 for  C. 
trachomatis  C1515-positive (wild type) specimens, 
and equalled 0.046 for specimens negative for  C. tra-
chomatis.  Negative controls included in this analysis 
(n = 6), consisting of 10,000 copies/mL of wild type 
(C1515)  C. trachomatis  RNA, yielded S/CO ratio values 
ranging from 0.016 to 0.112 (mean: 0.044); positive 
controls (n = 6) consisting of 1,000 copies/mL of IVT 
RNA corresponding to FI-nvCT (C1515T) rRNA yielded S/
CO ratio values ranging from 3.60 to 9.02 (mean: 6.38) 
(data not shown).
The analytical sensitivity of the new Aptima-format 
FI-nvCT surveillance assay for detecting in vitro tran-
script (IVT) RNA containing the  C. trachomatis  23S 
rRNA C1515T mutation using the 100,000 RLU cut-off 
was established by Probit analysis of a panel of six 
positive and one negative FI-nvCT RNA samples (n = 20 
replicates each panel member) (Figure 2). This analy-
sis established the 95% limit of detection (LOD) for 
the assay is 231 copies/mL in Aptima sample transport 
medium and 210 copies/mL in urine sample matrix, 
equivalent to ca 0.072 infectious units per mL (IFU/mL) 
and 0.065 IFU/mL, respectively (copies to IFU conver-
sion data not shown). 
Analytical specificity (cross-reactivity) and interfer-
ence (spike and recovery) of the assay against non-
target organisms potentially encountered in urogenital 
or extra-genital specimens was assessed by testing 
a minimum of ten replicates of each of 22 pools con-
sisting of 3 to 4 organisms per pool, encompassing 
59 bacterial, 2 yeast, 4 protozoal and 19 viral species 
at high titre (Table 1). All non-target organisms tested 
yielded negative results in the assay. To assess non-
target organism interference, 23S rRNA C1515T IVT RNA 
was spiked to a concentration of three times the assay 
95% LOD (660 copies/mL) and tested in the presence 
of the same high titre pools. All results were positive 
for the 23S rRNA C1515T-spiked specimens (Table 1) 
except for Panel 20, which was 95% positive. In addi-
tion, culture isolates of C. trachomatis serotypes A, B, 
Ba, C, D, E, F, G, H, I, J, K, L1, L2 and L3 (all containing 
the wild type base C1515 in the 23S rRNA) were tested 
at 1x105  IFU/mL each (except serotype G, which was 
tested at 3x104 IFU/mL). All serotypes tested (n = 5 rep-
licates each) yielded negative results in the assay with 
S/CO ratio values ranging from 0.129 to 0.248 (data not 
shown).
 
European validation of the Aptima-format 
surveillance assay for the Finnish new 
variant of C. trachomatis
Additional validation studies of the Aptima-format 
FI-nvCT surveillance assay using spiked specimens 
and clinical specimens was performed at the World 
Health Organization (WHO) Collaborating Centre 
for Gonorrhoea and other Sexually Transmitted 
Infections in Örebro, Sweden. The results of this 
validation are summarised in  Table 2. Briefly, all 10 
WHO  Neisseria gonorrhoeae  reference strains; 153 
isolates of 14 non-N. gonorrhoeae  Neisseria  species 
and three  Moraxella  species; 10  Trichomonas vagi-
nalis  (TV) samples, including the two TV ATCC 
strains 30001 and 50140; five reference strains of 
four non-TV  Trichomonas  species; nine  C. trachoma-
tis  strains of different genotypes and the Swedish 
new variant of  C. trachomatis  (SE-nvCT); four non-C. 
trachomatis  Chlamydia  species; 428 clinical  C. tra-
chomatis wild type positive AC2 specimens; 23 clinical 
specimens positive for  N. gonorrhoeae,  T. vaginalis, 
bacterial vaginosis and  Candida  species; and 443 
clinical AC2-negative specimens, were negative in the 
FI-nvCT assay. However, all 69 FI-nvCT positive clinical 
AC2 specimens (verified by 23S rRNA gene sequencing) 
were positive in the new Aptima-format FI-nvCT surveil-
lance assay (Table 2). 
Discussion
This study presents validation and verification data 
for a new research-use Aptima-format NAAT for detec-
tion of the FI-nvCT strain. The assay selectively detects 
with high sensitivity (100%) and specificity (100%)  C. 
Figure 1
Clinical specificity of the Aptima-format Finnish new 
variant of Chlamydia trachomatis (FI-nvCT) surveillance 
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CT: Chlamydia trachomatis; ES: endocervical swab; Neg: negative; 
Pos: positive; TP: PreservCyt ThinPrep liquid cytology; VS: 
vaginal swab.
a Signal-to-cut-off ratio values for the FI-nvCT assay are from 
testing clinical specimens obtained from a United States 
reference laboratory that are positive (n = 266) or negative 
(n = 188) for C. trachomatis by the Aptima Combo 2 assay. Of 
the 266 positive specimens: ES (n = 54); male and female urine 
(n = 71); VS (n = 68); TP (n = 73).
The dotted line represents the cut-off value established for the FI-
nvCT surveillance assay.
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trachomatis strains containing 23S rRNA with the C1515T 
mutation found to be the root cause of compromised 
detection in the AC2 assay and does not detect C. tra-
chomatis strains lacking this nt variance.
Genetic variation in  C. trachomatis, a highly preva-
lent bacterial STI [7], has historically been considered 
uncommon. However, a recent large-scale genomic 
analysis of geographically and temporally diverse  C. 
trachomatis  strains revealed a remarkable degree of 
homologous recombination and mutations that have 
occurred in the organism in the recent millennia [8]. 
This new understanding provides additional insight into 
the previous discovery in 2006 of a diagnostic-escape 
mutant of  C. trachomatis  that spread undetected in 
Sweden for 3 to 4 years before its discovery [9-12]. 
This SE-nvCT has a deletion in the plasmid DNA tar-
geted by two widely used diagnostic NAATs in use at 
that time [9], which allowed the SE-nvCT strain to reach 
high prevalence levels (> 60%) in some segments of the 
infected population [10].
The automated research-use only Aptima-format 
FI-nvCT surveillance test described here should facili-
tate the rapid completion of epidemiologic surveillance 
studies to estimate FI-nvCT prevalence and to track the 
geographic and temporal spread of this new diagnostic-
escape variant in people screened for STIs in Europe.
Figure 2
Analytical sensitivity as Probit 95% LOD of the Aptima-format Finnish new variant of Chlamydia trachomatis (FI-nvCT) 





























C1515T IVT RNA (copy/mL)
neg 10 50,000 150,000
STM LOD
Urine LOD
IVT: in vitro transcript; LOD: limit of detection; neg: negative; STM: sample transport medium.
Probit 95% LOD values for detection of RNA containing the C1515T sequence are 210 copies/mL for urine specimens, and 231 copies/mL for 
sample transport medium (STM) specimens.
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Table 1a
Cross reactivity and interference testing of non-target organisms with the Aptima-format Finnish new variant of Chlamydia 
trachomatis (FI-nvCT) surveillance assay on the Panther instrument, United States, 2019
Pool Organism Concentration
FI-nvCT negative
FI-nvCT RNA positive 
 
(3X LOD)
Number Positive S/CO Number Positive S/CO
1
Acinetobacter lwoffii 1e6 CFU/mL
0/10 0.048 10/10 2.015
Actinomyces israelii 1e6 CFU/mL
Alcaligenes faecalis 1e6 CFU/mL
Anaerococcus vaginalis 1e6 CFU/mL
2
Arcanobacterium haemolyticum 1e6 CFU/mL
0/10 0.036 10/10 2.635
Atopobium vaginae 1e6 CFU/mL
Bacteroides fragilis 1e6 CFU/mL
Bacteroides oralis 1e6 CFU/mL
3
Bifidobacterium adolescentis 1e6 CFU/mL
0/10 0.026 10/10 5.769
Bordatella parapertussis 1e6 CFU/mL
Campylobacter jejuni 1e6 CFU/mL
Campylobacter rectus 1e6 CFU/mL
4
Citrobacter koseri 1e6 CFU/mL
0/10 0.035 10/10 4.679
Corynebacterium diphtheria 1e6 CFU/mL
Corynebacterium genitalium 1e6 CFU/mL
Corynebacterium pseudodiptheriticum 1e6 CFU/mL
5
Eggerthella lenta 1e6 CFU/mL
0/10 0.050 10/10 5.638
Enterobacter cloacae 1e6 CFU/mL
Enterococcus faecalis 1e6 CFU/mL
Escherichia coli 1e6 CFU/mL
6
Fusobacterium necrophorum 1e6 CFU/mL
0/10 0.043 10/10 5.705
Fusobacterium nucleatum 1e6 CFU/mL
Gardnerella vaginalis 1e6 CFU/mL
Helicobacter pylori 1e6 CFU/mL
7
Haemophilus ducreyi 1e6 CFU/mL
0/10 0.036 10/10 5.485
Haemophilus parahaemolyticus 1e6 CFU/mL
Haemophilus parainfluenzae 1e6 CFU/mL
Klebsiella pneumoniae 1e6 CFU/mL
8
Lactobacillus acidophilus 1e6 CFU/mL
0/10 0.042 10/10 4.628
Legionella (Tatlockia) micdadei 1e6 CFU/mL
Legionella jordanis 1e6 CFU/mL
Leptotrichia buccalis 1e6 CFU/mL
9
Listeria monocytogenes 1e6 CFU/mL
0/10 0.061 10/10 4.554
Megasphaera type 1 1e6 CFU/mL
Mobiluncus curtisii 1e6 CFU/mL
Moraxella catarrhalis 1e6 CFU/mL
10
Mycoplasma genitalium 1e6 CFU/mL
0/10 0.034 10/10 5.514
Mycoplasma hominis 1e6 CFU/mL
Mycoplasma pneumoniae 1e4 CFU/mL
Neisseria gonorrhoeae 1e6 CFU/mL
11
Peptostreptococcus micros 1e6 CFU/mL
0/10 0.041 10/10 3.074
Propionibacterium acnes 1e6 CFU/mL
Staphylococcus aureus 1e6 CFU/mL




FI-nvCT RNA positive 
 
(3X LOD)
Number Positive S/CO Number Positive S/CO
12
Proteus vulgaris 1e6 CFU/mL
0/10 0.031 10/10 5.617
Shigella dysenteriae 1e6 CFU/mL
Shigella flexneri 1e6 CFU/mL
Shigella sonneri 1e6 CFU/mL
13
Stenotrophomonas maltophilia 1e6 CFU/mL
0/10 0.020 10/10 6.025
Streptococcus agalactiae 1e6 CFU/mL
Streptococcus anginosus 1e6 CFU/mL
Streptococcus pyogenes 1e6 CFU/mL
14
Ureaplasma parvum 1e6 CFU/mL
0/10 0.038 10/10 3.971
Ureaplasma urealyticum 1e6 CFU/mL
Veillonella parvula 1e6 CFU/mL
Burkholderia cepacia 1e6 CFU/mL
15
Clostridium difficile 1e6 CFU/mL
0/10 0.040 10/10 3.991
Prevotella bivia 1e6 CFU/mL
Candida albicans 1e6 CFU/mL
Cryptococcus neoformans 1e6 CFU/mL
16
Entamoeba histolytica 1e4 cells/mL
0/10 0.052 10/10 3.963
Giardia lamblia 1e4 cells/mL
Pentatrichomonas hominis 1e5 units/mL
Trichomonas vaginalis 1e5 cells/mL
17
Adenovirus type 07A 1e5 TCID50/mL
0/10 0.029 10/10 5.076
Coronavirus 229E 1e5 TCID50/mL
Coxsackievirus B3 1e5 TCID50/mL
Echovirus type 11 1e5 TCID50/mL
18
Enterovirus type 68 1e4 TCID50/mL
0/10 0.060 19/20 4.349
Epstein-Barr virus 1e6 copies/mL
Hepatitis B virus 1e6 IU/mL
Hepatitis C virus 1e5 IU/mL
19
HIV 1e5 copies/mL
0/10 0.073 37/40a 1.902
HPV 16 (SiHa cells) 1e4 cells/mL
HPV 18 (HeLa cells) 1e4 cells/mL
Human metapneumovirus type 20 1e6 TCID50/mL
20
HSV I 1e4 TCID50/mL
0/10 0.047 19/20 4.225
HSV II 1e4 TCID50/mL
Influenza A(H3N2) 1e3 TCID50/mL
Influenza B Massachusetts/2/12 1e3 TCID50/mL
21
Norovirus Group II 1e6 TCID50/mL
0/10 0.082 10/10 3.592Respiratory syncytial virus type B 1e5 TCID50/mL
Rhinovirus A16 1e5 TCID50/mL
22
Chlamydia pneumoniae 1e5 IFU/mL
0/10 0.033 10/10 3.219Chlamydia psittaci (GP1802) 1e5 IFU/mL
Chlamydia psittaci (GP1557) 1e5 IFU/mL
23 Control pool negative NA 0/15 0.031 NA NA
24 Control pool positive NA NA NA 15/15 7.14
CFU: colony forming unit; HMPV: human metapneumovirus; HPV: human papillomavirus; HSV: herpes simplex virus; IFU: inclusion forming 
unit; LOD: limit of detection: NA: not applicable; S/CO; signal-to-cut-off; TCID50: tissue culture infectious dose 50.
a Initial result at 37/40 (93%). Organisms in the panel were tested individually with FI-nvCT (n = 10 each) and were 10/10 (100%) positive for 
each.
S/CO: HIV: 6.171; HPV16: 2.537; HPV18: 6.396; HMPV: 4.894.
Table 1b
Cross reactivity and interference testing of non-target organisms with the Aptima-format Finnish new variant of Chlamydia 
trachomatis (FI-nvCT) surveillance assay on the Panther instrument, United States, 2019
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Table 2
Cross reactivity of non-target organisms (spiked samples) and detection in clinical specimens of the Aptima-format Finnish 
new variant of Chlamydia trachomatis (FI-nvCT) surveillance assay on the Panther instrument, Europe, 2019
Bacterial species or specimen Number tested FI-nvCT positive FI-nvCT negative
Neisseria gonorrhoeae WHO F, G, L, M, U, V, W, X, Y and Z 10 0 10
N. gonorrhoeae-positive AC2 specimens 5 0 5
N. animalis 1 0 1
N. bergeri 1 0 1
N. cinerea 9 0 9
N. elongata 3 0 3
N. flava 1 0 1
N. flavescens 90 0 90
N. lactamica 12 0 12
N. macacae 17 0 17
N. mucosa 18 0 18
N. oralis 1 0 1
N. perflava 62 0 62
N. sicca 9 0 9
N. subflava 6 0 6
N. meningitidisa 17 0 17
Moraxella catarrhalis 1 0 1
M. nonliquefaciens 1 0 1
M. osloensis 1 0 1
Trichomonas vaginalis (ATCC 30001 and ATCC 50140) 10 0 10
T. vaginalis-positive AC2 specimens 8 0 8
T. aotus (ATCC 50649) 1 0 1
T. gallinae (ATCC 30002, 30230) 2 0 2
T. stableri (ATCC PRA-412) 1 0 1
T. tenax (ATCC 30207) 1 0 1
Bacterial vaginosis-positive vaginal swabs 5 0 5
Candida spp.-positive vaginal swabs 5 0 5
C. trachomatis Ba, D, E, F, G, H, J, K and L2b 9 0 9
C. trachomatis wild type (C1515)-positive clinical AC2 specimens 428 0 428
C. trachomatis SE-nvCT 1 0 1
C. suis (ATCC VR-1474) 1 0 1
C. muridarum (ATCC VR-123) 1 0 1
Chlamydia pneumoniae (ATCC VR-2282, MBC011) 2 0 2
Chl. psittaci (MBC013) 1 0 1
C. trachomatis and N. gonorrhoeae-negative clinical AC2 specimens 443 0 443
FI-nvCT-positive clinical AC2 specimensb 69 69 -
ATCC: American Type Culture Collection; SE-nvCT: Swedish new variant of Chlamydia trachomatis; AC2: Aptima Combo 2; WHO: World Health 
Organization.
a Representing all major meningococcal clones spreading worldwide, including serogroups A, B, C, E, W, X, Y and Z.
b Confirmed by sequencing of the 23S rRNA gene.
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